The study made use of data from a prospective hospital-based cohort of pregnant women enrolled at the antenatal clinic and followed up at delivery between February and December 2019. Blood samples from mother-child pairs were evaluated for antibodies against Lassa virus. The study demonstrates a transplacental transfer of LASV IgG of 75.3% [60.0-94.0%], with a significant positive correlation between maternal and cord concentrations and a good level of agreement. The study also suggests that transfer may be more variable in women with \'de novo\' antibodies compared to those with pre-existing antibodies.
The study shows that maternal antibody levels play an important role in determining transfer efficiency of Lassa antibodies to the new-born; and while the evidence is preliminary, the study also suggests that transfer efficiency may be less stable in acute or recent infection, as such timing of vaccination before pregnancy, that is in women of childbearing age may be more appropriate for protection of both pregnant women and their neonates.
结果:该研究利用了在2019年2月至12月期间在产前诊所登记并在分娩时随访的前瞻性医院孕妇队列的数据。评估了来自母子对的血液样品的抗拉沙病毒抗体。该研究表明LASVIgG的经胎盘转移为75.3%[60.0-94.0%],母体和脐带浓度之间存在显着正相关,并且具有良好的一致性。该研究还表明,与具有预先存在的抗体的女性相比,具有“从头抗体”的女性的转移可能更加可变。
结论:该研究表明,母体抗体水平在确定拉沙抗体向新生儿的转移效率中起重要作用;虽然证据是初步的,该研究还表明,在急性或近期感染中,转移效率可能不太稳定,怀孕前接种疫苗的时间,也就是说,育龄妇女可能更适合保护孕妇及其新生儿。